The BVA-100 provides safe, accurate, objective quantification of blood volume status. Credit: PublicDomainPictures from Pixabay.

Daxor Corporation is seeking approval from the US Food and Drug Administration (FDA) for its next-generation blood volume analyser, Daxor BVA. 

Daxor BVA is designed for rapid, simple, and bedside patient care. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company submitted to the FDA through the 510(k)/CLIA-waiver dual pathway, with potential clearance for the analyser anticipated in the first half of this year.  

Daxor CEO and president Michael Feldschuh said: “Today marks a long-anticipated and momentous milestone in our continued commitment to our customers and patients, and to achieving our vision of optimal blood volume for all. 

“Funded under contract by the US Department of Defense, our next-generation analyser will deliver a level of speed, access, and accuracy to blood volume management that can significantly improve care and outcomes in medicine.” 

The Daxor BVA system is designed to quantify the intravascular blood, red blood cells, and plasma volumes directly. This provides healthcare professionals with critical data to optimise fluid management for patients.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The new device boasts a threefold increase in speed, simplified operation, portability, and the ability to perform analyses at the patient’s bedside compared to the existing Daxor BVA-100 system.  

These enhancements are expected to facilitate the integration of this advanced diagnostic tool into clinical routines, the company said. 

Currently, the Daxor BVA-100 system is being used daily in major centres across the US. More than 65,000 tests have been performed to evaluate blood volume using this device. 

Said to be the first diagnostic blood test cleared by the FDA, the BVA-100 provides safe, accurate, objective quantification of blood volume status and composition for use in a broad range of medical and surgical conditions.